Trial Profile
Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Neoadjuvant Chemotherapy Combining Gemcitabine and a Hedgehog Inhibitor (Vismodegib) in Patients With Resectable Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms NEOPACHI-001
- 07 Jul 2016 Status changed from recruiting to completed.
- 23 Aug 2014 Status changed from not yet recruiting to recruiting, as per European Clinical Trials Database record.
- 19 Nov 2012 New trial record